Skip to Content

Novelos Therapeutics, Inc. announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Sharon Weber, MD, Professor and Chief of Surgical Oncology and Medical Director of Surgical Oncology, Carbone Cancer Center, is hopeful that GLOW2 will provide surgeons with more accurate visualization of tumor margins during surgery.

To read more of Dr. Weber’s commentary on GLOW2 and to view the article in full, please click on the link below:

NOVELOS THERAPEUTICS DEVELOPING CLR1502 (GLOW2) CANCER-TARGETED OPTICAL IMAGING AGENT FOR INTRAOPERATIVE TUMOR MARGIN ILLUMINATION

webmaster@surgery.wisc.edu Copyright © 2016 The Board of Regents of the University of Wisconsin System